Why Rare Disease Patient Advocacy Groups Are the Missing Link in Clinical Trial Design

Published: 05 Jun 2026

Rare disease patient advocacy groups hold community trust, lived experience, and recruitment reach that sponsors cannot replicate alone. Yet advocacy is often engaged too late in trial design.

Early partnership improves protocol feasibility, inclusion criteria, site selection, and culturally responsive outreach — especially for underserved populations.

How to partner meaningfully

• Invite advocacy into protocol discussions before finalization
• Compensate community expertise and co-design engagement plans
• Use collaboration platforms to identify aligned advocacy partners by disease area

Explore our platform · Join the network · Our health equity mission